RESEARCH PAPER

Predictive Modeling of Drug Release Kinetics using ML Algorithms

Dr Jagadeesh Krishna[1*], Sudha .M[2], Poorvik .M[3]

[1*]Associate Professor & Head of the Department of BCA in Artificial Intelligence, SBRR Mahajana First Grade (Autonomous) College Affiliation: University of Mysore Email Id: jagadeeshkrishna.pgc@mahajana.edu.in
[2]Assistant Professor and Head of the Department, Department of Computer Application (MCA), Daksha First Grade College, Hootagalli, Mysore, Karnataka, INDIA, affiliated to University of Mysore, Email ID: sudha@dakshacollege.com
[3]Assistant Professor, Department of Computer Application (MCA), Daksha First Grade College, Hootagalli, Mysore, Karnataka, INDIA, affiliated to University of Mysore, Email ID: poorvik@dakshacollege.com

Abstract
The use of predictive modelling of drug release kinetics is significant to advanced drug delivery systems design and optimization. Although traditional mathematical models are common, they have several limitations in their applicability, including the fact that all are based on simplified assumptions and are incapable of describing complex, non-linear interactions among variables of formulation. Over the past years, machine learning (ML) has become a potent data-driven strategy that can overcome these constraints. The paper discusses how traditional kinetic models were developed into current ML models and how these models are used in sustained-release systems, long-acting injectables, polymeric matrices, and newer systems like 3D-printed and targeted drug delivery systems. Among the critical modeling methods, such as artificial neural networks, physics-informed models, surrogate modeling, and explainable AI, a discussion about the critical aspects of predictive accuracy and interpretability is presented. The paper also examines how one can integrate ML with process analytical technologies and manufacturing processes to make predictions and optimize drug release behavior in real-time. Although there has been a huge advancement, there are still issues of data availability, model validation and standardization. Future directions include hybrid and explainable methods of robust and translational predictive modeling.

Keywords: Drug release kinetics; Machine learning; Predictive modeling; Controlled drug delivery; Artificial intelligence
How to cite this article: Krishna J, Sudha M, Poorvik M. Predictive Modeling of Drug Release Kinetics using ML Algorithms. Int J Drug Deliv Technol. 2026;16(46s): 192-202. DOI: 10.25258/ijddt.16.46s.19

1. Introduction

Rational design of controlled and sustained drug delivery systems revolves around the ability to effectively characterize and predict the drug release kinetics. The pharmacokinetic profile of drugs directly influences their therapeutic efficacy, bioavailability, dosing regimen and patient adherence, making the issue of release behavior an important consideration during the development of pharmaceutical formulations. Mechanistic and semi-empirical mathematical equations such as the zero-order, first-order, Higuchi and Korsmeyer-Peppas equations have been used historically to characterize the release profiles of drugs. Even though these models do provide a helpful insight into the mechanisms of diffusion, erosion, and swelling, they often incorporate simplifying assumptions that limit their ability to be multi-component models and non-linear release mechanisms. Since drug delivery systems are becoming more and more complex, e.g., with complex polymer matrices, nanocarriers and stimuli-responsive materials, the predictive ability of traditional kinetic models is increasingly limited, especially with the high-dimensional and heterogeneous experimental conditions of the formulation variables.

This has been emphasized by the latest advances on the concept of computational modeling which have suggested that it is possible to employ data-driven approaches to overcome these shortcomings. Machine learning (ML) is a type of artificial intelligence, and it provides a more general model that can learn more non-linear interactions between formulation parameters and drug release behavior with no explicit mechanistic assumptions. More recent experiments have shown that with the help of experimental sets, it is possible to train the ML algorithms to learn the dissolution profiles and parameter of kinetics at a high precision. A case in point is Protopapa et al. proved that machine learning models could be effective in predicting drug release attributes when formulating tablets, showing that ML can extrapolate between formulation spaces and is capable of discovering hidden phenomena that are not modelled by conventional models. These methods allow replacing the empirical testing of the trial-and-error by predictive formulation design and optimal-based formulation design.

Simultaneously, in order to improve predictive performance and interpretability further, hybrid modeling methods a combination of mechanistic knowledge and data-driven methods have been suggested. These models combine the advantages of both fields by preserving the conceptual basis of classical kinetics and brings the capability of machine learning to the table. Alshahrani and colleagues were in a good position to show that hybrid techniques could be employed to enhance the validity and efficiency of drug release prediction especially when novel formulations

*Author for Correspondence: jagadeesh.krishna@hotmail.com

are being dealt with because empirical and only mechanistic models can never result in successful prediction. This is a promising step towards more dependent and scalable predictive pharmaceutics.

Artificial neural networks (ANNs) have been especially notable among the machine learning methods in modeling drug dissolution processes because of their capability to approximate complicated functional relationships. ANNs have been used to predict in vitro dissolution profiles very rapidly with indirect measurements like spectroscopic measurements and this has greatly saved time and cost of experimentations. Galata et al. demonstrated that ANN-based models can be effectively used to predict the extended-release tablet dissolution profiles with high accuracy, which can be used in real-time and high-throughput. These improvements notwithstanding, several issues persist such as lack of data, interpretability of models and the necessity of standardized datasets and validation criteria. Even though the body of literature on machine learning in pharmaceutics has grown at a quick rate, a lot of it has been scattered throughout particular formulation platforms, analytical technologies, or algorithm-driven applications. The literature has a tendency of referring to ML as a widely general phenomenon in pharmaceuticals, but there is limited literature that is concerned with the critical synthesis of its usage in predicting drug release kinetics as a particular field of prediction across various formulation classes. Moreover, the comparison of predictive accuracy, interpretability, translational relevance, and manufacturing integration, with the help of a single analytical framework, has received little attention. In this regard, the current narrative review is opportune in that it not only focuses on the development of ML-based drug release modeling beyond traditional and hybrid models into explainable and process-based systems, it also looks at how these techniques vary across sustained-release, implantable, targeted and advanced manufacturing-enabled dosage forms. It is thus a critical narrative synthesis that this review carries a three-dimensional form of modeling evolution, application specific to formulation and implementation pathway. In this way, it will attempt to elucidate the present condition of the field, unresolved scientific and translational research gaps and provide the future directions of how to develop strong, interpretable and clinically relevant predictive models of drug release kinetics.

2. Transition from Conventional to Data-Driven Models

As the history of drug release modeling in pharmaceutics shows, there is a transition in paradigm to data-driven predictive frameworks, instead of the determinist, equation-based ones. Kinetic models, although fundamental, are limited by predetermined assumptions about the behavior of diffusion, dissolution and matrices. These models are usually idealised and might be insufficient to model the complex interactions of formulation variables, material heterogeneity and environmental effects in the drug delivery systems of the modern day. With the increase of the use of multi-component excipients and sophisticated polymers in formulation design, purely mechanistic methods have proven to be more limiting, and a more flexible modeling approach is required.

As an answer to this, formulation approaches that utilize the power of machine learning and rely on data-based modeling have emerged as strong predictive and optimization tools for formulation. Contrary to the traditional formulation models, machine learning algorithms use experimental data for training purposes, thereby allowing the identification of non-linear relationships between input factors and dissolution results. This was achieved by Bharathi et al., who applied machine learning approaches for predicting the in vitro dissolution time of sustained-release tablets from raw materials data. According to the study, data-based modeling approaches enable the incorporation of multiple formulation characteristics into one predictive tool, reduce dependency on repetitive experimentation, and make in silico screening possible.

In particular, machine learning has proved successful for sustained and long-acting systems where release is controlled by complex physicochemical phenomena on a long-term scale. Bannigan et al. demonstrated that ML models exert the capability to hasten the design of polymeric long-acting injectables, as they allow quick prediction of release profiles and formulation functioning. This is the movement away of descriptive modeling toward prediction and optimization models that are able to deal with high-dimensional formulation spaces.

Although these have been made, there have been challenges about the transparency and interpretability of models, particularly in regulatory settings. Although black-box models are accurate, they usually lack information provided on what causes predictions. To overcome this, explainable AI (XAI) methods have been proposed. Robles and Samad suggested an interpretable ML architecture to predict the release of drug (long-acting injectables) and extracted the key formulation variables and yielded a higher interpretability and predictability.

Comparatively speaking, older models like Higuchi and Korsmeyer-Peppas are still useful to make mechanistic interpretations to simplified systems in cases where diffusion- or erosion-dominated behavior can be simulated. But they do not work as well with multivariate systems, non-linear and complex systems. Conversely, data-based models are good in modeling multivariate interactions and high-dimensional experimental relations. XAI offers a middle ground by enhancing transparency yet does not completely eliminate mechanistic understanding. In line with Table 1, this change should not be considered as a replacement of traditional kinetics, but an extension of the modeling toolbox to more predictive, interpretable and translational capabilities.

Table 1. Comparison of Traditional vs ML-Based Drug Release Models

Model Type	Approach	Strengths	Limitations	Applicability
Zero-order / First order	Mechanistic / empirical	Simple, well established, easy to interpret	Limited ability to capture complex multistage or non-linear release	Basic release systems, preliminary kinetic fitting
Higuchi / Korsmeyer–Peppas	Semi-empirical mechanistic	Mechanistic insight into diffusion and release behavior, widely accepted	Strong assumptions, reduced flexibility in heterogeneous and multivariable systems	Matrix tablets, diffusion-dominant systems, lower-dimensional formulations
ANN	Data-driven	Captures complex non-linear relationships, strong predictive performance	Black-box behavior, limited interpretability, dependent on data quality	Complex formulations, sustained-release systems, multivariable datasets
General ML models (e.g., RF, SVR, boosting)	Data-driven	Handles high-dimensional inputs, supports formulation screening and optimization	May lack mechanistic transparency, external validation often limited	Broad pharmaceutical prediction tasks, complex release systems
Hybrid models	Combined mechanistic + data-driven	Improved accuracy with partial interpretability, bridges theory and prediction	Higher implementation complexity, requires careful model design	Advanced formulations, translational modeling, mechanistically informed prediction
Explainable ML / XAI-assisted models	Data-driven with interpretability layer	Improves trust, identifies influential variables, supports scientific interpretation	Does not fully replace mechanistic explanation, interpretation may remain indirect	Regulatory-facing analysis, long-acting injectables, decision-support applications

3. ML in Advanced Drug Delivery Systems

Machine learning enabled advanced drug delivery systems represent a shift in generalized predictive modeling approaches to platform-specific, mechanistically informed formulation design. In comparison with traditional oral dosage delivery agents, systems like long-acting injectables (LAIs), microspheres made of poly-lactic glycoses, and targeted delivery systems are more amenable to modeling because they have multi-phase release characteristics, polymer degradation mechanisms, and even physiological effects. The patterns of release that are usually exhibited by these systems are non-linear and time-dependent and are hard to capture by classical kinetic equations. In this respect, machine learning offers an efficient mechanism of deriving predictive structure of heterogeneous data and assists in rational design of the complex delivery technologies.

An important breakthrough is the combination of physiological knowledge with predictive modeling using empirical data. While previous approaches focused on in vitro formulation properties exclusively, new models take advantage of incorporating physiological factors to achieve greater accuracy of predictions when related to in vivo behavior. Formulation LAI, proposed by Xiong et al., uses a physiology-informed ML approach to achieve this aim.

A key area of ML research is in PLGA microspheres because of their complex release mechanisms that are controlled by interacting variables, including polymer composition, particle size, drug loading, and degradation rate. Catapano et al. confirmed that the multidimensional relationships can be well modeled through the use of ML models in various experimental circumstances.

Neural network-based methods also increase predictive power, by allowing complete profiles of releases to be directly modeled, instead of modelling individual endpoints. Zhang et al demonstrated that non-linear properties of a dissolution data can be learned by a neural network, thus predicting all the release curve with accuracy, which are more informative to the formulation optimization.

There has also been expansion around machine learning with the incorporation of spectroscopic and analytical technology in the predictive capabilities. Consequently, Mahdi et al. determined that the combination of ML and Raman spectroscopy offers the possibility to project drug release in targeted systems extraordinarily quick and free of any harm, and the characterization of the materials can be simply linked to the operations of the systems.

Synthetically, the applications show that the performance of ML relies on the system complexity existing. Physiological integration is used to enhance the prediction of LAIs trans-translationally, multivariate interactions and time course behavior are demonstrated using ML in PLGA system, spectral integration is used to give quick judgment in targeted systems. None of the practices of the ML suggested in Table 2 is universally ideal and system specific complexity is to be used to choose the model.

Table 2. ML Applications in Advanced Drug Delivery Systems

Ref	System	ML Model	Input Variables	Output	Key Contribution

[7]	Long-acting injectables (LAI)	Physiology-based ML	Formulation + physiological parameters	Release profile prediction	Improved in vivo relevance and translational modeling
[8]	PLGA microspheres	Machine learning models	Polymer properties, particle size, formulation variables	Drug release behavior	Multivariable modeling of complex polymer systems
[9]	PLGA-based systems	Neural networks	Formulation parameters, time-series data	Full release curve	Temporal prediction of complete dissolution profiles
[10]	Targeted drug delivery systems	ML + Raman spectroscopy	Spectroscopic data	Release prediction	Non-destructive, rapid, real-time prediction potential

4. Foundations of ML-Based Drug Release Modeling (Reduced)

Machine learning-based modeling of drug release evolved methodological bases away toward flexible nonlinear prediction frameworks to more mechanistically motivated and interpretable computational frameworks. This development is an indication of the understanding that the relationship between drug dissolution and release is under complicated relations with the composition of the formulations, materials properties, process conditions and time dynamics. Classical statistical and empirical models can find it challenging to model these multidimensional interactions, particularly where the response surface is very non-linear or measuring interactions between two or more release mechanisms are involved. Here, four functional types can be used to comprehend ML-based drug release modeling: nonlinear predictive, mechanistically constrained, process-efficient surrogate, and explainability-oriented. This categorization makes it clear that the various ML methods serve different purposes and are not substitutes. The former is nonlinear predictive models, specifically artificial neural networks (ANNs) and genetic programming, which were two of the earliest computational intelligence methods to dissolution analysis. Mendyk et al. demonstrated these approaches had the potential to change the more heuristic approximation of dissolution modeling to a formal representation of these data. They have the advantage of nonlinear formulation-response relationships that are hard to model using more traditional mechanistic or regression-based models.

The second type is the mechanically constrained models, the most prominent being physics-informed neural networks (PINNs). PINNs introduce neuromorphic principles by integrating physical principles into training, providing the freedom of a neural network and the discipline of a mechanistic system. Qureshi et al. showed how mass transport and release kinetics can be included as constraints making these models particularly applicable to more complicated systems where there are overlaps between diffusion, degradation and erosion.

The third category is the so-called surrogate models which are models used to approximate experimental or manufacturing outcomes in an efficient way in terms of processes. Dissolution testing is quite resource-intensive; thus, they are applicable in rapid screening and real time quality assessment. Galata et al. reported evidence of the applicability of ML-generated surrogate models to perform real-time release testing with NIR spectral, compression force and particle size distribution. The greatest contribution they make is that they make rapid and scale efficient prediction which can be operationalized.

A fourth and still more important type is explainable orientated modeling. Explainable AI (XAI) helps answer this question by assisting the uncertainties of highly flexible ML systems, and distinguishing variables, areas or signal features that explain predictions in the most prominent way. Al-Baghdadi et al. continued such direction with Grad-CAM analysis of convolutional neural network models trained on additional surface dissolution imaging data that learn features based on additional surface dissolution phenomena, such as visual learning of spatial dissolution phenomena.

These four types combined ANN and genetic programming to nonlinear prediction, PINNs to mechanistic integration, surrogate models to efficient approximation, and XAI to interpretability stand out as the cornerstones of the methodology of current ML-based drug release modeling. Table 3, in brief, shows that this functional taxonomy can be used to understand how various ML approaches can be used to enhance the science of drug release and why the use of various predictive and translational approaches should be contingent on the desired goal.

Table 3. ML Techniques Used in Drug Release Modeling

Technique	Type	Key Feature	Advantage	Limitation
ANN	Deep learning / nonlinear predictive modeling	Learns complex nonlinear mappings between formulation inputs and release outputs	High predictive accuracy in multivariable systems	Limited interpretability; black-box behavior
Genetic Programming	Evolutionary symbolic modeling	Derives mathematical relationships directly from data	Can generate explicit functional expressions	Sensitive to data quality and model complexity

PINN	Hybrid physics-informed ML	Integrates physical laws with neural network learning	Improved mechanistic consistency and extrapolative reliability	More complex implementation and training
Surrogate Models	ML-based approximation	Fast prediction of experimental or process outcomes	Supports real-time release testing and manufacturing decision-making	Approximation error may reduce fidelity under unrepresented conditions
XAI / Grad-CAM	Explainable ML	Adds transparency to model predictions by identifying influential features or regions	Enhances trust, interpretability, and scientific usability	Limited standardization and does not fully replace mechanistic explanation

5. ML for Formulation Optimization

Another of the most applicable contributions related to pharmaceutics field by machine learning is its predictive accuracy in the context of optimization of formulations in addition to this accuracy. Sequential experimental compensation One of the traditional ways to develop drug delivery has been through factorial design and empirical explanation of the dissolution results. Though effective, these methods are still not efficient when the performance of the formulation involves many interacting variables including the structure of the polymer and the ratio of the drug loading and excipient, the matrix structure and the processing conditions. Optimization, which must be capable of exploration of the complex non-linear design space, is required in sustained release devices and also in implantable devices where small change in parameters can greatly affect the release kinetics. Formulation optimization taking place in this review can be seen as the combination of not only parameter optimization, but also the selection of suitable excipient or polymer combinations, optimization of burst performance and sustained performance, and orchestration of the release behavior to therapeutic objectives. Machine learning is enabling this broader role through transforming the formulation development process which has been more of an iterative process and transforming it to a data-driven process of data-space exploration and decision-making.

Artificial neural networks (ANNs) have been especially effective as they are able to learn non-linear relationships between the formulation inputs and the release responses. Correspondingly, instead of merely predicting dissolution results, ANN-based models could locate parameter settings to the targeted therapeutic objectives. An example of how predictive models can be actively used to control formulation design was exemplified by Maderuelo et al. who used ANNs to fine-tune kinetics of metronidazole release of sustained-release colonic hydrophilic matrices.

The importance of machine learning is increased further with implantable delivery systems where diffusion, swelling, degradation, and geometry of devices determine their release behavior. To elucidate this complexity, Benkoe et al. integrated experimental design and ANN-based modelling to not only predict values of release rates via implantable matrix but to gain a more insightful perspective as to how release control works. Their research indicates that the predictive accuracy in terms of ML can also be enhanced and contributes to a better understanding of the performance of a formulation.

More recently, further innovations in deep learning have been able to predict intrinsic drug properties, which influence release behaviour, extending this optimization framework. Yoo et al. showed that deep learning might predict drug properties involved in the pharmaceutical design and development which offers an additional level of guidance to the initial formulating design. As these characteristics such as solubility, molecular weight and lipophilicity have a direct impact on diffusion and interaction with the matrix, integration of these predictions into the formulation process can minimize the uncertainty and improve the alignment between the dosage form design and drug properties.

Taken together, these pieces of evidence suggest that machine learning is re-inventing formulation optimization as a multilevel predictive problem, designed as a matrix, implantable system engineering and drug-specific property appraisal. As a concise recap of the results in Table 4, ML is not only becoming an auxiliary modelling tool, but a key element of intelligent and efficient formulation optimization.

Table 4. ML-Based Formulation Optimization Studies

Ref	System	ML Model	Optimization Goal	Key Outcome
[15]	Colonic hydrophilic matrix	ANN	Sustained-release optimization	Improved release kinetics and formulation guidance
[16]	Implantable matrices	ANN-based modeling	Drug release rate optimization	Better prediction of release rate and insight into underlying mechanisms
[17]	Drug property prediction for formulation design	Deep learning	Early-stage property-informed optimization	Improved decision-making for formulation design through prediction of drug-relevant properties

6. Modeling Across Different Release Systems

The predictive modeling of drug release kinetics needs to consider the variety of drug delivery platforms and the unique principles that regulate the release behavior of each platform. Formulation architecture, material properties, degradation pathways and the physiological environment modulate drug release. The predictive models in this connection should consider internalises of

immediate-release formulations, 3D-printed dosage system, hydrogel, and dissolution in dynamic gastrointestinal conditions. Even though this review is based on ML-based prediction, other computers and hybrid research have been provided that can illuminate system specific variables that may be included in the ML frameworks.

The predictability of a model for immediate release (IR) systems depends on the effects of GI motility, hydrodynamics, and disintegration dependent on the formula itself. While IR formulations might be considered less complicated, in vitro performance might differ based on different physiological states. Staniszewska et al. showed that machine learning combined with DoE and biorelevant devices were able to recreate variation in dissolution, highlighting the significance of physiological variability in the process.

On the other hand, structure plays a significant role in affecting drug release when using 3D printing techniques for producing pharmaceutical formulations. The nature of the release is influenced by geometrical factors such as surface-area volume fraction and porosity. Windolf and others have shown that these geometric properties can even be used as the major predictive input that can be considered as a change towards design-based modeling.

Hydrogel systems further complicate behaviour of materials that dynamically change with time, such as swelling and degradation. The hybrid modeling methods employed by Sheth et al. help predict the release of degradable hydrogel and have recognized the mechanistic variables, which then need to be included in any future ML model.

Gastric dissolution modeling at the physiological level, incorporates formulation behavior into a dynamic biological setting. Seo and Mittal demonstrated that a combination of computational models, which use fluid mechanics and gastric transport mechanisms, is more accurate in prediction and multiscale integration is necessary.

These systems, based on the synthesis perspective, have pointed out that predictive effectiveness is a consideration of the governing force of predominance. IR system physiological development, 3D-printed system structural development, hydrogel system materials dynamics, and gastric modeling biological scenario. As clearly outlined in Table 5, no generalized strategy of modeling and successful prediction is to match the modeling strategy with the complexity of new systems.

Table 5. ML Across Drug Delivery Platforms

Ref	System Type	Key Governing Factor	Modeling Approach	Insight / Contribution
[18]	Immediate-release formulations	Gastric motility and hydrodynamics	ML + Design of Experiments (DoE)	Captures physiological variability in dissolution behavior
[19]	3D printed oral dosage forms	Geometry and structural design	ML-based modeling	Demonstrates geometry-driven release prediction
[20]	Hydrogel-based systems	Polymer degradation and network dynamics	Hybrid modeling (experimental + mathematical)	Identifies key material variables for predictive modeling
[21]	Gastric dissolution systems	Physiological environment and fluid dynamics	Computational / physiology-based modeling	Integrates biological transport processes into release prediction

7. Historical and Classical ANN Applications

The first application of ANNs for predicting drug release kinetics in the pharmaceutics field led to the current development of predictive models. The potential of the ANN model in maximizing the dissolution profile of sustained-release formulations, in particular, salbutamol sulfate matrix formulations, where the complex interaction between the formulation properties and release characteristics could be predicted without having to resort to rigid mathematical modeling. This article highlighted the capability of the ANN architecture in coping with the nonlinearity in drug delivery systems.

Using these background approaches, there have been several studies that further developed these approaches by exploring the potential of machine learning applications in increasingly complicated formulation challenges, such as the prediction of physical stability of amorphous solid dispersions. The prediction of formation and stability of stable amorphous systems via hot-melt extrusion technology has used machine learning algorithms that include formulations with process parameters. The above transformation is the transition from simple ANN-based optimization approach to more sophisticated models that solve multifactorial challenges of formulation development.

8. Integration with Manufacturing and Process Analytics

The maturity of machine learning-based drug release modeling is increasingly manifested in the fact that it is starting to be used together with pharmaceutical manufacturing and process analytics. Although initial uses were made in post hoc prediction of dissolution behavior, more recent uses have been made to operate in real world applications in formulation design, process control, and quality assurance processes. The importance of this transition is that the development of the industrial pharmaceutics does not only demand precise forecasts of the release kinetics but also the capability to incorporate the forecasts into the

manufacturing space that can be scaled. As a result of this, the combination of computational intelligence, state-of-the-art manufacturing and process analytical technologies is transforming the way that the drug release performance of a product is designed, monitored, and controlled throughout the product lifecycle.

As clear as it may be, one of such developments is the 3D printing of pharmaceuticals. Additive manufacturing provides the means to design dosage form geometry, internal architecture, and material distribution in a highly customized fashion, which offers highly customized drug release profiles. However, this flexibility leads to the high complexity of the processes as the interactions between many different variables, such as printing parameters, polymer properties and infill structure, predict this release behavior. Kassa et al. have shown that it is possible to tackle this complexity using computational intelligence by associating process variables with desired release outcomes. In their contribution, they point to the fact that machine learning can be employed as a predictive tool in a mature manufacturing environment but can be employed as a technology that facilitates design in personalized pharmaceutics.

Combination with machine learning with process analytical technologies also improves applicability of process analytical technology to industry through real-time, or close to real time, prediction of key quality attributes. Of these, near-infrared (NIR) spectroscopy has become a useful tool to characterize, non-destructively, and within a short period of time during the manufacturing process. AI data have the potential to be used to predict the performance of documents downstream in the future, without the need to test them extensively offline with the help of machine learning and the use of NIR data to predict these outcomes. This was demonstrated by Munir et al. through inline NIR measurements based on machine learning to predict the mechanical properties and dissolution profiles of the PLA-Aspirin formulations. This practice explains the way process regulated data could be explicitly related to effective release outcomes, which could be used to monitor quality ahead of time.

Translating, the developments are indicative of a change in conventional offline dissolution testing to inline or at-line predictive control. This is well coherent with the principles of Quality by Design (QbD), and process analytical technology (PAT) in which the quality of products is incorporated into the manufacture process instead of being tested after production. Systems based on machine learning allow real-time release testing, adjusting processes dynamically, and continually monitoring formulation performance, which is especially insightful in complex dosage forms that are susceptible to changes in processes.

These benefits notwithstanding, there are a few challenges which restrict the large-scale industrial implementation. Strong model behavior with batches, variability with material and instrument performance remains hard to obtain given that most research is still founded on controlled laboratory data. There are problems like the calibration drift, the reproducibility of the data, and reproducibility of cross-scales that may profoundly influence the predictive reliability. Additionally, regulatory approval is another major obstacle, because the implementation of ML-based predictive systems involves open validation procedures, lifecycle controlling, and regular functioning under industrial regimes.

Altogether, the combination of machine learning and manufacturing analytics is a major advance towards the functionalization of predictive pharmaceutics. It allows replacing an existent evaluation with the ongoing and data-based control of the product quality. With the growing connection of drug release prediction with real-time process measurements and analytical tools, the future efficacy of this technology in transferring to industry will need to be linked with better validation systems, standard methodology, and compliance with regulatory standards.

9. ANN in Modern Formulation Design

Despite the extension of the field of machine learning in pharmaceutics to encompass deep learning, physics-informed models, surrogate models, and explainable AI, the field of artificial neural networks (ANNs) still occupies a very specific and pragmatic niche in the work of formulation design. They are not only historically relevant, but also appropriate to a general pharmaceutical reality: many studies of formulations are based on and require moderate size datasets of experimental quality too small to be learned by more data-hungry architectures, yet too complex to be learned by simple regression or mechanistic equations. ANNs provide a good compromise between flexibility of the model and feasibility in this environment.

ANNs are useful due to the fact that they are highly suited to formulation data structure. The interaction of various factors, such as polymer ratio, excipient composition, compression force, tablet hardness and drug loading normally affect the modified release dosage forms. They can be non-linear relationships, yet portable datasets are will in practice fall too small to warrant very high-complexity deep learning pipelines. In these scenarios, ANN models can represent the multidimensional formulation-performance relationships without the need of scale of data or computing infrastructure of newer architectures. This was the benefit that Ibrić et al. had in the assessment and optimization of modified release solid dosage forms.

ANNs also happen to be especially handy when formulation maximization (as opposed to the purely mechanistic interpretation) is the goal. In practice, the researcher frequently requires models capable of finding interesting parameter combinations relating to a desired release profile, when the system is too complicated to be represented by a single mechanistic equation. Under these conditions ANNs provide usefulness as a decision support tool in exploration of the design space. Sheth and Acharya portrayed this ongoing utility by using optimization with ANN to alter release dosing forms.

Notably, the fact that ANNs are still being actively used should not be exhibited as an act of opposition to the progress of methods, but rather as a sign of proper

ecological niche among the larger predictive sector. More sophisticated deep learning methods could be beneficial, where large, varied or image-intensive data exists; and more physics-informed and hybrid methods might be better where the goal is to interpret mechanistically. In comparison, ANNs are appealing to music when datasets are not too large, the number of variables is great, and they are mutually contained, and practical prediction or optimization are what are required at the moment.

Combined, ANN-based modeling would have a high relevance in the current formulation design since it will overcome a historic blind spot between pharmaceutical modeling traditions and resource consuming machine learning methods. ANNs still offer a good balance of predictive power, efficiency and usability in the case of modified release research where there is limited data available, yet the complexity of the formulation is high. That renders them a valuable part of data-driven, astute development of the formulations.

10. Recent Advances in ML-Driven Drug Release Prediction

Recent high-impact articles indicate that machine-learning identically based drug release forecasting is approaching a more adult stage, where forecastive modelling is no longer regarded as a post facto analysis tool, but as a part of formulation development, mechanistic interpretation, and performance enhancement. Prior research in this area was mostly interested in demonstrating that the machine learning algorithms were capable of more easily fitting dissolution or release data than traditional kinetic equations. Recent progresses are more integrative though with experimental design, mechanistic reasoning and multivariate analytics to create not only correct, but more translationally useful, models. The transformation in pharmaceutics can be regarded as a more general shift in which machine learning is becoming a commonly used methodology to relate material behavior, experimentation, and prediction of decision-making in all complex drug delivery systems.

A direction in this evolution is the instant incorporation of machine learning into experimental release studies in nanocarrier systems. The nanoparticles of PLA are a particularly difficult system since the release of nanoparticles is determined by several interacting factors, such as polymer composition, particle size, drug delivery efficiency, package degradation rate, and medium conditions. Yu Sun et al. have tackled this complexity through a combination of machine learning and in vitro experiments to examine drug release of PLGA nanoparticles. This work is also important in that it demonstrates that experimental data generation and computational learning can be implemented in a mutually reinforcing structure, such that predictive models can be refined and formulation insight enhanced in an iterative manner.

The mechanism variables, upon the basis of which can be measured the release behavior, have been strengthened, at once, however, by the new achievements in the science of dissolution. Though intrinsic dissolution modeling is not a machine learning technique per se, it offers a conceptualized approach of existing predictive models by elucidating the interdepending nature of dissolution rate, solubility and hydrodynamic behavior of the respective layers. Those can be applied to the study by Mattusch et al. as his work is highlighting the fact that the ML based prediction must be in touch with physically meaningful descriptions as well as not to rely on the statistical performance alone. This justifies the usefulness of group predictive methods that have developed physicochemical theories.

The other important innovation is the hybrid structures, which combine conventional regression models and machine learning models. This was evidenced by Yadav et al. who used the partial least squares and machine learning regression models in predicting drug release in targeted drug delivery applications. Their models represent a middle-path approach to modeling in that the traditional regression provides structural meaning, while machine learning allows for nonlinear form response functions. Such an integration would be particularly useful in a system-specific context, where release depends not only on quantitative formulation characteristics but also on more complex interactions.

Taken as a whole, the articles demonstrate how current trends regarding ML in the field differ from historical precedents for four key reasons: being more experimental, more concerned with mechanisms, more hybrid in nature, and more about translation rather than concept. Rather than using machine learning as an alternative to standard drug science research, the new approach uses the machine learning aspect as part of an overall predictive system combining experimentation, mechanism understanding, and statistical methods. The next generation of drug release models will feature this shift in perspective, and it will assist in translating computing technology advances into useful tools for designing formulations and developing therapeutics.

11. Discussion

The replacement of traditional modeling of drug release by machine learning-based prediction is part of a larger change to pharmaceutics falling away from equation-constrained modeling in favor of inference based on data. Classical kinetic models like zero-order, first-order, Higuchi and Korsmeyer-Peppas are useful, as they are mechanistically interpretable and familiar in terms of the insight into diffusion-, swelling-, and erosion driven release However, there exist advanced formulation systems, which cannot be predicted using these models since they are based on a model of non-linear, multi-variable interaction, especially within polymeric matrix, multi-act, long-acting injection, and target release systems. The conventional models perform effectively in retrospective analysis rather than in prospective prediction in such cases.

The first evident advantage of the ML method is that this algorithm learns complicated patterns without relying on any predefined mechanistic pattern from experiment data. As opposed to the conventional models, the ML algorithm can predict release profiles and kinetics for

more complicated interactions, namely non-linear interactions, or combined formulation variables. This shows that hybrid methods also make the approach more reliable, indicating that ML is an extension, but not a substitute of conventional models [2].

The primary trade-off of ML is the trade-off between interpretability and accuracy although it has these advantages. Elastic models like neural networks can display good predictive experiments but are black boxes, which obstruct the analysis of underlying processes. This is especially applicable in drugs, on which scientific knowledge and legal goodwill rest on transparency. To some extent Explainable ML methods solve this problem by discovering relevant variables [6], but the trade-off between prediction and interpretability is not yet balanced.

The current limitations may be divided into four groups: data, methodological, validation and, translational gaps. Small, formulation-specific datasets that limit generalizability and benchmarking are sources of data limitations. Methodological gaps exist since it lacks any standardized structures of variable choice, model comparison and model performance. External or cross-platform validation is also confined to the gaps between validation as well the validation, which is an external and limited, is founded on internal as compared to external that creates problems with reproducibility. The presence of difficulties in translation is due to the lack of interpretability, non-standardization, and specification when using ML to address regulatory systems such as PAT and QbD.

Overall, the flexibility in prediction, the possibility to combine multivariable in machine learning, and the value of mechanistic interpretation is clear to the conventional models, which lack the cost of their divinity. The field is hence narrowing down to worked-out interface, foreseeable accuracy and intelligibility. In the future, standardized datasets, outside validation plans, interpretable combination models, and greater control with manufacturing systems and regulatory systems will be required. These issues still have to be resolved before the ML-driven drug release prediction becomes highly promising and yet ready to become a common pharmaceutical practice.

12. Conclusion

The history of modeling drug release will be marked by a decisive change towards more detailed, data-driven predictive models, built on the older, equation-based models. Even though classical kinetic models have played a significant role in mechanistic insight, they have been found wanting regarding multivariate complex formula solutions hence giving way to more practical approaches. Machine learning has emerged as a powerful substitute, can capture non-linear associations, brings along a vast assortment of formulation parameters and is potentially capable of forecasting extended-release profiles with a higher-level precision. Its versatility and growing use in pharmaceutics today is shown by its application in sustained-release systems, implantable and 3D-printable dosage forms, as well as in physiologically relevant environments. Besides its predictive accuracy, ML-based models enable optimization of formulation, reduction of the number of experiments, and real-time process analytics. Scientific and practical relevance of the techniques has been improved due to improve interpretability and compatibility with mechanistic understanding such as hybrid modeling, surrogate models and explainable AI. However, there are data set, model validation and a weakness of standardization challenges which prohibit greater use. These concerns will be critical towards the robustness and acceptance of regulation. Machine learning is not only improving prediction, but it is even revolutionizing formulation science in to being predictive, design driven. The development steps that will follow will be based on GI standard data structure, explainability, and rigorous translational validation. Lastly, the huge impact will be most profound with hybrid methods that utilize experimental results, mechanistic knowledge and computational perception within one platform to cast drug delivery.

References

[1] C. Protopapa, A. Siamidi, A. A. Eneli, M. Elbadawi, and M. Vlachou, “Machine learning predicts drug release profiles and kinetic parameters based on tablets’ formulations,” The AAPS Journal, vol. 27, no. 5, p. 124, 2025.

[2] S. M. Alshahrani, H. F. Alotaibi, and M. Alqarni, “Modeling and validation of drug release kinetics using hybrid method for prediction of drug efficiency and novel formulations,” Frontiers in Chemistry, vol. 12, p. 1395359, 2024.

[3] D. L. Galata, M. F. A. Elbadawi, C. Protopapa, A. A. Eneli, and M. Vlachou, “Fast, spectroscopy-based prediction of in vitro dissolution profile of extended release tablets using artificial neural networks,” *Pharmaceutics*, vol. 11, no. 8, p. 400, 2019.

[4] M. Bharathi, R. K. S. S. R. Krishna, S. V. R. K. Prasad, and P. V. R. Chowdary, “A data-driven approach to predict the in vitro dissolution time of sustained-release tablets using raw material databases and machine learning algorithms,” *Pharmacia*, vol. 71, pp. 1–7, 2024.

[5] P. Bannigan, M. J. D. Clancy, J. D. Humphreys, A. T. R. Walters, A. M. Healy, and D. J. Brayden, “Machine learning models to accelerate the design of polymeric long-acting injectables,” *Nature Communications*, vol. 14, no. 1, p. 35, 2023.

[6] K. N. Robles and M. D. Samad, “Predicting early and complete drug release from long-acting injectables using explainable machine learning,” *arXiv preprint*, arXiv:2601.02265, 2026.

[7] P. Xiong, Y. Zhang, H. Wang, L. Chen, and J. Liu, “FormulationLAI: A physiology-based machine learning framework for accelerated development of long-acting injectable formulations,” *Journal of Controlled Release*, p. 114418, 2025.

[8] A. F. Catapano, L. Zheng, X. Yuan, and K. Yuan, “Machine learning for predicting drug release behavior of PLGA microspheres,” in AMIA Annual Symposium Proceedings, vol. 2024, p. 212, 2025.

[9] Z. Zhang, B. Zhang, R. Chen, Q. Zhang, and K. Wang, "The prediction of the in vitro release curves for PLGA-based drug delivery systems with neural networks," Pharmaceutics, vol. 17, no. 4, p. 513, 2025.

[10] W. A. Mahdi, A. Alhowyan, and A. J. Obaidullah, "Combination of machine learning and Raman spectroscopy for prediction of drug release in targeted drug delivery formulations," Scientific Reports, vol. 15, no. 1, p. 25139, 2025.

[11] A. Mendyk et al., "From heuristic to mathematical modeling of drugs dissolution profiles: application of artificial neural networks and genetic programming," Computational and Mathematical Methods in Medicine, vol. 2015, p. 863874, 2015.

[12] D. A. Qureshi, K. Shukla, and V. Srivastava, "Drug release modeling using physics-informed neural networks," arXiv preprint arXiv:2602.09963, 2026.

[13] D. L. Galata, M. Elbadawi, C. Protopapa, A. A. Eneli, M. Vlachou, and A. Heuer, "Real-time release testing of dissolution based on surrogate models developed by machine learning algorithms using NIR spectra, compression force and particle size distribution as input data," *International Journal of Pharmaceutics*, vol. 597, p. 120338, 2021.

[14] A. Al-Baghdadi, M. Alsharif, H. Alzahrani, A. Alotaibi, and A. Alghamdi, "Explainable AI in pharmaceutics: Grad-CAM analysis of surface dissolution imaging using convolutional neural networks," *Pharmaceutics*, vol. 18, no. 4, p. 481, 2026.

[15] C. Maderuelo, R. Arévalo-Pérez, and J. M. Lanao, "Building artificial neural networks for the optimization of sustained-release kinetics of metronidazole from colonic hydrophilic matrices," Pharmaceutics, vol. 17, no. 11, p. 1451, 2025.

[16] E. Benkő, Á. Farkas, Z. Kónya, B. Farkas, and G. Regdon Jr., "Predicting drug release rate of implantable matrices and better understanding of the underlying mechanisms through experimental design and artificial neural network-based modelling," *Pharmaceutics*, vol. 14, no. 2, p. 228, 2022.

[17] S. Yoo, J. Kim, and G. J. Choi, "Drug properties prediction based on deep learning," Pharmaceutics, vol. 14, no. 2, p. 467, 2022.

[18] M. Staniszewska, A. K. Szymańska, M. K. Kędzierska, and K. Winnicka, "A rational approach to predicting immediate release formulation behavior in multiple gastric motility patterns: a combination of a biorelevant apparatus, design of experiments, and machine learning," *Pharmaceutics*, vol. 15, no. 8, p. 2056, 2023.

[19] H. Windolf, R. Chamberlain, and J. Quodbach, "Predicting drug release from 3D printed oral medicines based on the surface area to volume ratio of tablet geometry," Pharmaceutics, vol. 13, no. 9, p. 1453, 2021.

[20] S. Sheth, R. J. R. U. S. De Silva, A. A. K. Kar, and S. R. Raghavan, "Predicting drug release from degradable hydrogels using fluorescence correlation spectroscopy and mathematical modeling," *Frontiers in Bioengineering and Biotechnology*, vol. 7, p. 410, 2019.

[21] J. H. Seo and R. Mittal, "Computational modeling of drug dissolution in the human stomach," Frontiers in Physiology, vol. 12, p. 755997, 2022.

[22] F. Chaibva, M. Burton, and R. B. Walker, "Optimization of salbutamol sulfate dissolution from sustained release matrix formulations using an artificial neural network," Pharmaceutics, vol. 2, no. 2, pp. 182–198, 2010.

[23] J. Jiang, Y. Zhang, H. Wang, X. Li, and L. Chen, "The applications of machine learning to predict the forming of chemically stable amorphous solid dispersions prepared by hot-melt extrusion," *International Journal of Pharmaceutics: X*, vol. 5, p. 100164, 2023.

[24] F. M. Kassa, S. H. Youssef, Y. Song, and S. Garg, "Use of computational intelligence in customizing drug release from 3D-printed products: A comprehensive review," *Pharmaceutics*, vol. 17, no. 5, p. 551, 2025.

[25] N. Munir, M. A. Khan, A. R. Tariq, and S. I. Shah, "In-line NIR coupled with machine learning to predict mechanical properties and dissolution profile of PLA-Aspirin," *Functional Composite Materials*, vol. 5, no. 1, p. 14, 2024.

[26] S. Ibrić, J. Djurić, M. Parojčić, and Z. Djurić, "Artificial neural networks in evaluation and optimization of modified release solid dosage forms," *Pharmaceutics*, vol. 4, no. 4, pp. 531–550, 2012.

[27] T. S. Sheth and F. Acharya, "Optimization and evaluation of modified release solid dosage forms using artificial neural network," Scientific Reports, vol. 14, no. 1, p. 16358, 2024.

[28] Yu Sun, Shuhuai Qin, Yingli Li, Naimul Hasan, Yan Vivian Li, and Jiangguo Liu, "Machine learning integrated with in vitro experiments for study of drug release from PLGA nanoparticles," Scientific Reports, vol. 15, p. 4218, 2025.

[29] A. M. Mattusch, G. Schaldach, J. Bartsch, and M. Thommes, "Intrinsic dissolution modeling: interdependence between dissolution rate, solubility, and boundary layer thickness," Pharmaceutics, vol. 17, no. 5, p. 570, 2025.

[30] A. Yadav, B. Jayaprakash, L. H. Jasim, M. Kundlas, M. Y. Anad, A. Srivastava, et al., "Implementing partial least squares and machine learning regressive models for prediction of drug release in targeted drug delivery application," Scientific Reports, vol. 15, no. 1, p. 22461, 2025.